RPID News & Events

Reports Q1 revenue $8.0M, consensus $7.6M. Cash, cash equivalents, short-term investments, and restricted cash were approximately $23M as of March 31. "Our first quarter results reflect strong and consistent execution across the business," said Robert Spignesi, CEO. "Strong consumable revenue drove nearly 30% growth in recurring revenue, underscoring the strength of our installed base and utilization trends. We continue to see robust customer interest in QC automation and are increasingly engaged in strategic discussions with customers on enterprise-level deployments of the Growth Direct platform and broader integration into company-wide automation strategies."

The company reaffirmed its FY26 total revenue guidance range of $37.0M-$41.0M including a range of 30 to 38 Growth Direct system placements, at least 25 system validations and gross margin percentage of approximately 20%.

Lake Street notes that Rapid Micro Biosystems reported Q4 revenue in line with its January pre-release and established 2026 revenue guidance of $37M-$41M, compared to the firm's estimate of $39.8M and consensus of $39.9M. Shares are trading down 21% in reaction, which the firm thinks is "an unwarranted, but also an attractive situation for investors who take the time to look deeper." Rapid's ability to continue to extend its breadth and depth across the pharmaceutical manufacturing sector "should make it an attractive acquisition target in the coming years," contends the analyst, who keeps a Buy rating and $8 price target on the shares.